Rigel Pharmaceuticals | RIGL - Loan Capital


Rigel Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Agenus USD 169.66M 146.06M Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 538.1M 323.22M Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
MacroGenics USD 70M 256K Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60.57B 1.08B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 1.15B 383.26M Dec/2025
Veracyte USD 0 0 Mar/2025